Han JL et al / Acta Pharmacol Sin 2003 Apr; 24 (4): 327-331
1-adrenergic
receptor subtypes in human right gastroepiploic artery1
HAN Jiang-Li2, ZHANG You-Yi, LÜ Zhi-Zhen, MAO Jie-Ming2, CHEN Ming-Zhe2, HAN Qi-De3
Institute of Vascular Medicine, 2Department of Cardiovasology, Third Hospital, Peking University, Beijing 100083, China
1 Project supported by the Major State Basic Research Development Program of People's Republic of China (G2000056906) and the National Natural Science Foundation of China (No 30070872, 30171083).
3 Correspondence to Prof HAN Qi-De. Phn 86-10-6209-2306. Fax 86-10-6201-5681. E-mail hanqd@bjumu.edu.cn
Received 2002-04-15 Accepted 2002-11-11
KEY WORDS alpha-1 adrenergic receptors; right gastroepiploic artery; vasoconstriction; adrenergic alpha- antagonists; RS17053; 5-MU; BMY7378; WB4101; chlorethylclonidine
ABSTRACT
AIM: To study the functional
1-adrenergic
receptor (
1-AR) subtypes
in human right gastroepiploic artery (RGA). METHODS: The effects of
2-AR,
1-AR,
and
1-AR subtype selective
antagonists on norepinephrine (NE)-induced vasoconstriction in isolated human
RGA were observed by contractile function experiment. RESULTS: Cumulative
concentration-response curves for NE were competitively antagonized in RGA by
2-AR selective antagonist
yohimbine (pA2 6.82±0.28, slope 1.12±0.40),
1-AR
selective antagonist prazosin (pA2 9.77±0.22, slope 0.90±0.22),
1A-AR selective antagonists
RS17053 (pA2 8.42±0.20, slope 0.93±0.20) and 5-MU
(pA2 8.42±0.22, slope 0.88±0.18),
1D-AR
selective antagonist BMY7378 (pA2 6.84±0.32, slope 1.05±0.17),
and
1A-,
1B-AR
selective antagonist WB4101 (pA2 8.88±0.20, slope 1.15±0.16).
The correlation coefficients between these pA2 values of
1-AR
selective antagonists with pKi values of which obtained from
1A-,
1B-
and
1D-AR cloned cells
are 0.95, 0.82, and 0.42. After the vessels were pretreated by chlorethylclonidine
(CEC), an
1B- and
1D-AR
irreversible alkylating agent, the pD2 values were changed
from 5.9±0.5 to 5.6±0.6 and the maximal contraction was changed from
(8.9±3.2) g to (8.0±3.2) g, respectively. The difference was not significant.
CONCLUSION: In human RGA, the contraction response is mainly mediated
by
1-AR, of which
1A-AR
plays an important role, whereas
1B-
and
1D-AR are not involved in
the contraction response.
INTRODUCTION
1-Adrenergic receptor
(
1-AR) is an important
mediator, which contributes to the regulation of vascular activity, and is involved
in almost all-vascular smooth muscles to cause contraction response induced
by norepinephrine (NE).
1-AR
is subdivided into three subtypes (
1A,
1B, and
1D-AR)
by pharmacological techniques with subtype-selective antagonists and molecular
biological techniques. The corresponding cDNA coding for these receptors had
been cloned by means of molecular biological methods[1,2]. The distribution
of
1-AR and
1-AR
subtypes has been extensively characterized in rat and rabbit vessels using
functional studies and molecular biological methods[3-5]. However,
very little is known regarding the distribution of
1-AR
in human vessels. Right gastroepiploic artery (RGA) is an alternate conduit
used in coronary artery bypass graft (CABG) because of its similarity to internal
mammary artery (IMA). The RGA is reported to exhibit better contractility to
NE than the IMA, but comparable endothelium-dependent relaxation[6].
However, it is unknown which subtype of
1-AR
mediates NE-induced contraction. In this study the functional role of
1-AR
and its 3 subtypes in human RGA was investigated.
MATERIALS AND METHODS
Norepinephrine, yohimbine, propranolol, prazosin,
desmethylimipramine, normetanephrine, and
acetylcholine were purchased from Sigma.
8-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)-8-azaspiro (4,5)
decane-7-dionedihydrochloride) (BMY7378), 2-(2,6-dimethoxyphenoxyethyl) aminomethyl-1,
4-benzo-dioxane (WB4101), 5-methyl-urapidil (5-MU), and
chlorethylclonidine (CEC) were purchased from Research Biochemicals.
N-(2 -(2-cyclopropylmethoxy) ethyl)
5-choro-
-dimethyl-1H-indole-3-thylamine
(RS17053) was provided by Roche Bioscience.
Organ bath experiments Human undistended RGA from patients (mean age, 61 a±3 a; 14 male and 2 female; range 40 to 74 years old) were obtained during gastrectomy, respectively. The vessels were immediately placed in Krebs' solution of the following composition (mmol/L): NaCl 120, NaHCO3 20, KCl 5.45, NaH2PO41.2, MgCl2 1.2, CaCl2 2.5, glucose 10, and disodium edetic acid 0.04 (saturated with 95 % O2 and 5 % CO2). The vessels were then dissected free of connective tissue, cut into 2-mm ring segments for in vitro contractile studies. They were carefully denuded of endothelium by inserting a small forceps into the lumen and gently rolling the ring backwards and forwards in the dissecting chamber. The lack of functional endothelium was confirmed by the absence of endothelium-dependent relaxation of acetylcholine (10 mmol/L) in raised tone preparations induced by NE.
Desmethylimipramine 0.1
mol/L, normetane-phrine
1
mol/L(to block neuronal
and extraneuronal uptake of NE, respectively) and propranolol 10
mol/L(to block
-adrenoceptors)
were included in the incubation solution (yohimbine 0.1
mol/L
was added into the incubation solution when needed). The preparations were mounted
at 37 ºC in 10-mL organ baths containing Krebs' solution saturated with
95 % O2 and 5 % CO2, and attached to force displacement
transducer. The preparations were equilibrated at an optimal resting tension
of 3.0 g for 1 h, and primed twice with 10 µmol/L NE. After thorough washing,
NE-cumulative concentration-response curve (CRC) was generated, followed by
another 30-min washing. RGA were then incubated in turn with increasing amounts
of yohimbine, prazosin, WB4101, 5-MU, RS17053, and BMY7378 for 40 min, after
that 3 NE-CRC were generated in the presence of the above antagonists, EC50
values and 95 % confidence limits were calculated for all CRC. The pA2
values were calculated by Schild plot. RGA were incubated with CEC 50 µmol/L
for 30 min; after 40-min washing (the solution without CEC), pD2
values of NE and maximal contraction were determined.
Statistics Data were presented as mean±SD. Statistical analysis was performed by Student't test.
RESULTS
Effects of
-AR selective antagonists
on blood vessel contraction induced with NE In RGA NE caused the vasoconstriction
in a concentration-dependent manner. Cumulative concentration-contractile response
curves for NE (NE-CRC) were obtained with pD2 value (5.9±0.5)
and the maximal contraction (8.9 g±3.2 g). Prazosin (1, 3, and 10 nmol/L)
and yohimbine (0.1, 0.3, and 1 µmol/L) competitively inhibited NE-induced
contraction in a concentration-dependent manner. The pA2 values
and slopes for antagonists were shown in Tab 1 and Fig 1.
Tab 1. The pA2 values and slopes of
-AR
selective antagonists inhibiting NE-induced contraction in RGA. Mean±SD.
aP>0.05 vs 1.
Fig 1. Concentration-contractile response curves and Schild plot for antagonism
of norepinephrine-induced contraction by
-AR
and
1-AR subtype selective
antagonists in human RGA. Yohimbine (0.1, 0.3, and 1
mol/L);
prazosin (1, 3, and 10 nmol/L); WB4101 (3, 10, and 30 nmol/L); 5-MU (30, 100,
and 300 nmol/L); RS17053 (10, 30, and 100 nmol/L); BMY7378 (0.3, 1, and 3
mol/L).
Effects of
1-AR
subtype selective antagonists on blood vessel contraction induced with NE
WB4101 (3, 10, and 30 nmol/L), 5-MU (30, 100, and 300 nmol/L), RS17053 (10,
30, and 100 nmol/L) and BMY7378 (0.3, 1, and 3 µmol/L) also competitively
inhibited NE-induced contraction in a concentration-dependent manner in RGA.
The pA2 values and slopes for antagonists were shown in Tab
2 and Fig 1.
Tab 2. pA2 values and slopes of
1-AR
selective antagonists inhibiting NE-induced contraction in RGA. Mean±SD.
aP>0.05 vs 1.
Effect of CEC on NE-CRC Before and after CEC 50 mmol/L pretreatment, the pD2 values (5.9±0.5 vs 5.6±0.6, n=4) and the maximal contraction (8.9 g± 3.2 g vs 8.0 g±3.2 g, n=4) of NE-CRC had no change (P>0.05, Fig 2).
Fig 2. Concentration-contractile response curve for antagonism of norepinephrine-induced
contraction by CEC 50
mol/L in human
RGA.
DISCUSSION
The use of arterial grafts instead of vein grafts in CABG has been demonstrated
through the years to improve survival and to reduce the recurrence of myocardial
ischemia and the occurrence of late myocardial infarction. The current trend
in CABG is toward complete arterial revascularization. RGA is one of the arteries
used for CABG with better clinical results[7,8], because it is related
to the better contraction and dilation functions[9]. The good endothelial
function of the RGA might be important for graft function and patency, whereas
the enhanced contractility may facilitate vasospasm, especially in the presence
of high circulating level of catecholamines. Therefore it is important to investigate
the primary functional
1-AR
subtype, which contributes to NE-induced vessel contraction. In the present
studies, we used
1-AR
and
1-AR subtype selective
antagonists as tools to assess the function of
1-AR
subtypes, which contribute to NE-induced contraction in RGA.
In functional experiments,
1
-AR selective antagonist prazosin antagonized NE-induced
contraction with higher affinity than that of
2-AR selective antagonist yohimbine
(pA2 values were 9.77±0.22
vs 6.82±0.28). Because the slopes of prazosin and
yohimbine were not significantly different from unity, it
indicated that there was one site binding of
-AR in RGA and the contraction response was mainly
mediated by
1-AR.
Further more, we studied the effect of
1-AR subtype selective antagonist on the NE-induced
contraction response of RGA.
1A-AR subtype selective antagonists, including 5-MU and RS17053,
antagonized NE-induced contraction with higher affinity
(pA2 values were 8.42 respectively), whereas
BMY7378, an
1D-AR subtype selective
antagonist, antagonized NE-induced contraction with
lower affinity (pA2 values was 6.84). In addition, the
slopes for these drugs in Schild plot were not
significantly different from unity. It indicates that
1A-AR might be the primary subtype, which contributes to
NE-induced contraction. The further correlation analysis
was performed. The pAi values for
1-AR subtype selective antagonists obtained from functional study
were correlated with their pKi values measured in
radioligand binding competition assays with membranes
from HEK293 cells expressing
1A,
1B, and
1D-AR in our previous
study[10]. The values for the correlation coefficient
r were 0.95, 0.82, and 0.42. And the best correlation is with
1A-AR (P<0.05). It confirms that
1A-AR is a main subtype, which contributes to NE-induced contraction. Because
there has no
1B-AR subtype selective antagonist
now, we used CEC, an
1B and
1D-AR irreversible alkylating agent in functional study. Before
and after RGA were pretreated by CEC, the
pD2 values and the maximal contractile response for NE were
unchanged. These results indicated strongly that in
human RGA, NE-induced contraction was mainly mediated by
1A-AR subtype.
In conclusion,
1A-AR mainly contributes
to the NE-induced contraction in human RGA. This result implies that
1A-AR antagonist can be used
as an antispastic drug when RGA is employed for CABG.
REFERENCES
1-adrenoceptor.
Consensus update. Pharmacol Rev 1995; 47: 267-70.
1-adrenoceptor
subtype in rat aorta and renal artery. Chin Sci Bull 1996; 41: 749-52.
1-adrenoceptor
subtypes in rat vessels. J Beijing Med Univ 1999; 31: 516-9.
1-Adrenoceptor
subtypes mediating inotropic responses in rat heart. J Pharmacol Exp Ther
1999; 291: 826-36.